Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab

被引：0

作者：

Alcala, C. ^{[1
]}

Quintanilla-Bordas, C. ^{[1
]}

Gascon-Gimenez, F. ^{[2
]}

Sempere, A. P. ^{[3
]}

Navarro, L. ^{[4
]}

Carcelen-Gadea, M. ^{[5
]}

Belenguer, A. ^{[6
]}

Landete, L. ^{[7
]}

Mallada, J. ^{[8
]}

Canizares, E. ^{[9
]}

Carratala, S. ^{[1
]}

Cubas, L. ^{[1
]}

Gil-Perotin, S. ^{[1
]}

Dominguez, J. A. ^{[2
]}

Perez-Miralles, F. ^{[1
]}

Castillo, J. ^{[1
]}

Casanova, B. ^{[1
]}

机构：

[1] Univ & Polytech Hosp La Fe, Neuroimmunol Unit, Valencia, Spain

[2] Univ Hosp Clin Valencia, Valencia, Spain

[3] Hosp Gen Univ Alicante, Alicante, Spain

[4] Univ Gen Hosp Elche, Elche, Spain

[5] Consortium Univ Gen Hosp Valencia, Valencia, Spain

[6] Univ Gen Hosp Castello, Castellon de La Plana, Spain

[7] Univ Hosp Doctor Peset, Valencia, Spain

[8] Univ Gen Hosp Elda, Elda, Spain

[9] Univ Hosp Ribera, Alzira, Spain

来源：

MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P817

引用

页码：672 / 673

页数：2

共 50 条

[1] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Finn Sellebjerg
Morten Blinkenberg
Per Soelberg Sorensen
[J]. CNS Drugs, 2020, 34 : 269 - 280
[2] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Sellebjerg, Finn
Blinkenberg, Morten
Sorensen, Per Soelberg
[J]. CNS DRUGS, 2020, 34 (03) : 269 - 280
[3] Anti-CD20 monoclonal antibodies in multiple sclerosis
Moreno Torres, Irene
Garcia-Merino, Antonio
[J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
[4] Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: Ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis
Kappos, L.
Leppert, D.
Tinbergen, J.
Gerber, M.
Hauser, S. L.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1876
[5] Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis
Kappos, L.
Leppert, D.
Tinbergen, J.
Gerber, M.
Hauser, S. L.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 424 - 424
[6] Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study
Carmen Alcalá
Carlos Quintanilla-Bordás
Francisco Gascón
Ángel Perez Sempere
Laura Navarro
María Carcelén-Gadea
Lamberto Landete
Javier Mallada
Emmanuel Cañizares
Antonio Belenguer
Sara Carratalá
José Andrés Domínguez
Francisco Carlos Pérez-Miralles
Sara Gil-Perotín
Raquel Gasqué
Laura Cubas
Jéssica Castillo
Bonaventura Casanova
[J]. Journal of Neurology, 2022, 269 : 3676 - 3681
[7] Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study
Alcala, Carmen
Quintanilla-Bordas, Carlos
Gascon, Francisco
Sempere, Angel Perez
Navarro, Laura
Carcelen-Gadea, Maria
Landete, Lamberto
Mallada, Javier
Canizares, Emmanuel
Belenguer, Antonio
Carratala, Sara
Dominguez, Jose Andres
Perez-Miralles, Francisco Carlos
Gil-Perotin, Sara
Gasque, Raquel
Cubas, Laura
Castillo, Jessica
Casanova, Bonaventura
[J]. JOURNAL OF NEUROLOGY, 2022, 269 (07) : 3676 - 3681
[8] Real-world evidence of anti-CD20 monoclonal antibodies in chilean patients with multiple sclerosis
Del-Canto, A.
Garcia, L.
Aylwin, E.
Jurgensen-Heinrich, L.
Guzman-Carcamo, I.
Gutierrez-Calquin, L.
Barrera-Hormazabal, A.
Cruz, J. P.
Bravo-Grau, S.
Pelayo, C.
Soler, B.
Uribe-San-Martin, R.
Carcamo, C.
Ciampi, E.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 383 - 384
[9] Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Florou, Despoina
Katsara, Maria
Feehan, Jack
Dardiotis, Efthimios
Apostolopoulos, Vasso
[J]. BRAIN SCIENCES, 2020, 10 (10) : 1 - 13
[10] Treatment of multiple sclerosis with Anti-CD20 antibodies
Barun, Barbara
Bar-Or, Amit
[J]. CLINICAL IMMUNOLOGY, 2012, 142 (01) : 31 - 37

← 1 2 3 4 5 →